- Home
- GYRE vs BTBT Comparison
GYRE vs BTBT Comparison
Compare GYRE & BTBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- BTBT
- Stock Information
- Founded
- GYRE 2002
- BTBT 2015
- Country
- GYRE United States
- BTBT United States
- Employees
- GYRE N/A
- BTBT N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- BTBT Finance: Consumer Services
- Sector
- GYRE Health Care
- BTBT Finance
- Exchange
- GYRE Nasdaq
- BTBT Nasdaq
- Market Cap
- GYRE 897.1M
- BTBT 1.1B
- IPO Year
- GYRE N/A
- BTBT 2018
- Fundamental
- Price
- GYRE $8.21
- BTBT $3.17
- Analyst Decision
- GYRE
- BTBT Strong Buy
- Analyst Count
- GYRE 0
- BTBT 3
- Target Price
- GYRE N/A
- BTBT $6.33
- AVG Volume (30 Days)
- GYRE 80.3K
- BTBT 40.7M
- Earning Date
- GYRE 08-11-2025
- BTBT 08-14-2025
- Dividend Yield
- GYRE N/A
- BTBT N/A
- EPS Growth
- GYRE N/A
- BTBT N/A
- EPS
- GYRE 0.02
- BTBT N/A
- Revenue
- GYRE $102,189,000.00
- BTBT $102,037,923.00
- Revenue This Year
- GYRE $21.04
- BTBT $20.87
- Revenue Next Year
- GYRE $89.64
- BTBT $38.28
- P/E Ratio
- GYRE $170.09
- BTBT N/A
- Revenue Growth
- GYRE N/A
- BTBT 52.44
- 52 Week Low
- GYRE $6.11
- BTBT $1.69
- 52 Week High
- GYRE $19.00
- BTBT $5.74
- Technical
- Relative Strength Index (RSI)
- GYRE 60.94
- BTBT 52.55
- Support Level
- GYRE $6.62
- BTBT $2.96
- Resistance Level
- GYRE $7.47
- BTBT $3.24
- Average True Range (ATR)
- GYRE 0.46
- BTBT 0.27
- MACD
- GYRE 0.12
- BTBT -0.02
- Stochastic Oscillator
- GYRE 99.09
- BTBT 52.04
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.